Savolitinib (volitinib, AZD6094, HMPL-504): Future Directions

Toni K. Choueiri

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute presents Savolitinib (volitinib, AZD6094, HMPL-504): Future Directions at the 2016 annual International Kidney Cancer Symposium.

Savolitinib (volitinib, AZD6094, HMPL-504): Future Directions

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Savolitinib (volitinib, AZD6094, HMPL-504): Future Directions

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia